FIGURE 1.

Study schematic. Sixteen patients received 400 mg mavorixafor every day for 9 weeks. Following 3 weeks of mavorixafor monotherapy, 6-week combination therapy was initiated by the addition of pembrolizumab (intravenous infusion). Sampling occurred at baseline, week 4 (post-monotherapy), and week 9 (post-combination therapy).